Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas.
The mortality rate for patients with ovarian carcinomas is high and the available prognostic factors are insufficient. The use of biomarkers may contribute to better prediction and survival for these patients. We aimed to study the gene and protein expressions for 7 potential biomarkers, to determine if it is possible to use them as prognostic factors. Genes selected from our previous microarray analysis (2006), CLU, ITGB3, TACC1, MUC5B, CAPG, PRAME and TROAP, were analyzed in 19 of the tumors with quantitative real-time polymerase chain reaction (QPCR). We found that CLU and ITGB3 were more expressed in tumors from survivors and PRAME and CAPG were more expressed in tumors from deceased patients. None of the other 3 genes were significantly differently expressed. The protein expressions of CLU, ITGB3, PRAME and CAPG were analyzed in 43 of the tumors with western blot for semiquantitative analysis. We established that the mRNA and protein expressions correlated and that all 4 proteins were significantly differently expressed. Further, immunohistochemistry (IHC) was used to localize the expression of the proteins in the tumor samples. According to our results, the 4 biomarkers CLU, ITGB3, PRAME and CAPG may be used as prognostic factors for patients with stage III serous ovarian adenocarcinomas.
Partheen
Karolina
K
Department of Oncology, University of Gothenburg, Gothenburg, Sweden. karolina.partheen@gu.se
Levan
Kristina
K
Osterberg
Lovisa
L
Claesson
Ingela
I
Fallenius
Ghita
G
Sundfeldt
Karin
K
Horvath
György
G
D000230:Adenocarcinoma / Q000401:mortality* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000235:genetics; D014408:Biomarkers, Tumor / Q000032:analysis*; D051152:Clusterin / Q000032:analysis* / Q000235:genetics; D018284:Cystadenocarcinoma, Serous / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D039661:Integrin beta3 / Q000032:analysis* / Q000235:genetics; D008840:Microfilament Proteins / Q000032:analysis* / Q000235:genetics; D008875:Middle Aged; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000032:analysis* / Q000235:genetics; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology; D016133:Polymerase Chain Reaction; D011379:Prognosis
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C495242:CLU protein, human; D051152:Clusterin; C061248:ITGB3 protein, human; D039661:Integrin beta3; D008840:Microfilament Proteins; D009687:Nuclear Proteins; C404944:PRAME protein, human; C066575:CAPG protein, human